Literature DB >> 12360048

Chordoid glioma of the third ventricle: a report of two new cases, with further evidence supporting an ependymal differentiation, and review of the literature.

Basile Pasquier1, Michel Péoc'h, Alan L Morrison, Emmanuel Gay, Dominique Pasquier, Sylvie Grand, Marc Sindou, Nicolas Kopp.   

Abstract

The term chordoid glioma of the third ventricle was first used to describe a rare and slowly growing neoplasm of uncertain histogenesis, with chordoid appearance, occurring preferentially in middle-aged women. Herein we report two additional examples of this novel entity together with a literature review based on the 25 cases previously published. Our review fully confirms the strikingly stereotyped clinical, neuroradiologic, and pathologic features of this unique tumor. The female/male ratio was 1.7:1, and the age range was 24-70 years (mean 44.9 years). In all 27 cases imaging findings were similar showing a well-defined mass (mean 2.8 cm in largest dimension), ovoid in shape, hyperdense on CT scans, with uniform and intense contrast enhancement, arising in the hypothalamic/suprasellar/third ventricular region. Histologically, the main consistent characteristics were cords and clusters of epithelioid cells within an abundant mucinous and often vacuolated background. Mitoses were sparse or absent and anaplastic features, endothelial proliferation, and necrosis were not identified. Lymphoplasmacytic infiltrates with Russell bodies were frequent throughout the tumor and its interface with adjacent brain parenchyma. Most of the tumor cells revealed a strong and diffuse expression of vimentin and glial fibrillary acidic protein. Additionally, the vast majority of tumors showed focal coexpression of cytokeratins, CD34, S-100 protein, and epithelial membrane antigen; the MIB-1 labeling indices were uniformly low. Surprisingly for a glioma assigned WHO grade II, the 19 patients with an available but short follow-up (mean 22.5 months; range 6-68 months) experienced a rather poor outcome (three recurrences and seven deaths), probably reflecting the anatomic site of the neoplasm that precludes a complete surgical excision rather than its histologic composition. Ultrastructural examination of 10 cases demonstrated findings in line with a glial derivation and a putative ependymal origin such as cytoplasmic intermediate filaments, microvilli, intermediate junctions or desmosomes, and focal basal lamina formation. In our case no. 1, and for the first time in this tumor, we observed sparse and abnormal cilia in an aberrant juxtanuclear location, a further argument for considering chordoid glioma as a subtype of ependymoma. However, a better understanding of the biologic behavior and histogenesis of this distinctive clinicopathologic entity needs to be investigated with a larger series. Nevertheless, taking into account its strikingly consistent anatomic localization, its unique histopathologic and immunohistochemical profile, in conjunction with the most recent and convincing ultrastructural arguments, we suggest that chordoid glioma of the third ventricle could be better classified as chordoid ependymoma of the lamina terminalis area.

Entities:  

Mesh:

Year:  2002        PMID: 12360048     DOI: 10.1097/00000478-200210000-00010

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  17 in total

1.  CD99 is expressed in chordoid glioma and suggests ependymal origin.

Authors:  Alfredo E Romero-Rojas; Julio A Díaz-Pérez; Lina M Ariza-Serrano
Journal:  Virchows Arch       Date:  2011-11-20       Impact factor: 4.064

Review 2.  Prognostic factors for recurrence and complications in the surgical management of primary chordoid gliomas: A systematic review of literature.

Authors:  Leonel Ampie; Winward Choy; Jonathan B Lamano; Kartik Kesavabhotla; Qinwen Mao; Andrew T Parsa; Orin Bloch
Journal:  Clin Neurol Neurosurg       Date:  2015-08-19       Impact factor: 1.876

3.  Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.

Authors:  Ankur R Sangoi; Mohanpal S Dulai; Andrew H Beck; Daniel J Brat; Hannes Vogel
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

4.  Podoplanin is expressed in subsets of tumors of the central nervous system.

Authors:  Junji Shibahara; Takeshi Kashima; Yoshinao Kikuchi; Akiko Kunita; Masashi Fukayama
Journal:  Virchows Arch       Date:  2006-01-13       Impact factor: 4.064

5.  Cytology of chordoid meningioma: a series of five cases with emphasis on differential diagnoses.

Authors:  Philip C W Lui; Tony K F Chau; Steve S Wong; Patrick P L Lau; Gary M K Tse; Teresa M M Thomas; Ho Keung Ng
Journal:  J Clin Pathol       Date:  2006-07-12       Impact factor: 3.411

6.  Atypical presentations of solitary fibrous tumors of the central nervous system: an analysis of unusual clinicopathological and outcome patterns in three new cases with a review of the literature.

Authors:  Nestor M Pakasa; Basile Pasquier; Marie-Laure Chambonnière; Alan L Morrison; Abir Khaddage; Anne Gentil Perret; Jean Marc Dumollard; Fabrice G Barral; Michel Péoc'h
Journal:  Virchows Arch       Date:  2005-05-31       Impact factor: 4.064

7.  Chordoid glioma: ten years of a low-grade tumor with high morbidity.

Authors:  Ruth-Mary Desouza; Istvan Bodi; Nick Thomas; Henry Marsh; Matthew Crocker
Journal:  Skull Base       Date:  2010-03

8.  Extraventricular unusual glioma in a child with extensive myxoid change resembling chordoid glioma.

Authors:  R Goyal; R K Vashishta; S Singhi; M Gill
Journal:  J Clin Pathol       Date:  2007-11       Impact factor: 3.411

9.  Chordoid Glioma with Intraventricular Dissemination: A Case Report with Perfusion MR Imaging Features.

Authors:  So Yeon Ki; Seul Kee Kim; Tae Wook Heo; Byung Hyun Baek; Hyung Seok Kim; Woong Yoon
Journal:  Korean J Radiol       Date:  2016-01-06       Impact factor: 3.500

Review 10.  Chordoid glioma: report of a case with unusual histologic features, ultrastructural study and review of the literature.

Authors:  Jeffrey J Raizer; Teena Shetty; Philip H Gutin; Eugenie A Obbens; Andrei I Holodny; Cristina R Antonescu; Marc K Rosenblum
Journal:  J Neurooncol       Date:  2003-05       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.